Sstr2, anti-Sstr2 antibody drugs and Sst-image have been developed for diagnosis and therapy in pituitary and neuroendocrine tumors (42, 43); signaling-mediated plasma membrane resurfacing of Sstr2 can fine-tune pituitary hormone release (44). This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.